PE20180796A1 - Macrociclos peptidicos contra acinetobacter baumannii - Google Patents

Macrociclos peptidicos contra acinetobacter baumannii

Info

Publication number
PE20180796A1
PE20180796A1 PE2018000242A PE2018000242A PE20180796A1 PE 20180796 A1 PE20180796 A1 PE 20180796A1 PE 2018000242 A PE2018000242 A PE 2018000242A PE 2018000242 A PE2018000242 A PE 2018000242A PE 20180796 A1 PE20180796 A1 PE 20180796A1
Authority
PE
Peru
Prior art keywords
alkyl
hydrogen
individually selected
acinetobacter baumannii
cyano
Prior art date
Application number
PE2018000242A
Other languages
English (en)
Inventor
Alexander Alanine
Julien Beignet
Konrad Bleicher
Bernhard Fasching
Hans Hilpert
taishan Hu
Dwight Macdonald
Stephen Jackson
Sabine Kolczewski
Carsten Kroll
Adrian Schaeublin
Hong Shen
Theodor Stoll
Helmut Thomas
Amal Wahhab
Claudia Zampaloni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20180796A1 publication Critical patent/PE20180796A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Referido a un compuesto de Formula (I), en donde X1 es C-L1-R11 o N; X2 es C-L2-R12 o N; X3 es C-L3-R13 o N; X4 es C-L4-R14 o N, con la salvedad de que no mas de tres de X1, X2, X3 y X4 sean N; X5 es C-L5-R15 o N; X6 es C-L6-R16 o N; X7 es C-L7-R17 o N; X8 es C-L8-R18 o N, con la salvedad de que no mas de tres de X5, X6, X7 y X8 sean N; R1 es -(CH2)m-heteroarilo o -(CH2)m-heterocicloalquilo, entre otros; R2, R4 y R6 se seleccionan cada uno de forma individual entre hidrogeno, alquilo C1-7, entre otros; R3 es alquilo C1-7, -(CH2)n-NR20R21, entre otros; R5 es hidrogeno, alquilo C1-7, hidroxi-alquilo C1-7, entre otros; R5´ es hidrogeno o alquilo C1-7; R7 y R8 se seleccionan cada uno de forma individualmente hidrogeno, alquilo C1-7, haloalquilo C1-7, entre otros; R11, R12, R13, R14, R15 Y R16 se seleccionan cada uno de forma individual entre hidrogeno, halogeno, ciano, alquilo C1-7, entre otros; R17 es hidrogeno, halogeno, ciano, entre otros; R18 es hidrogeno, halogeno, ciano, alquilo C1-7, haloalquiloC1-7, entre otros. R21 y R23 se selecciona cada uno individualmente entre hidrogeno y alquilo C1-7; L1, L2, L3, L4, L5, L6, L7 y L8 se seleccionan cada uno individualmente entre un enlace simple, -C(O)-, -SO2-, -(CH2)p-, -CH=CH-, entre otros; m es 1, 2, 3, o 4; n es 1, 2, 3, o 4; o es 0, 1, 2, 3, o 4; p es 1, 2, 3, o 4; q es 1, 2, 3, o 4; r es 1, 2, 3, o 4; asi como sales farmaceuticamente aceptables de los mismos. Tambien se refiere a un proceso para la fabricacion de dicho compuesto, composiciones farmaceuticas que los comprenden, y su uso como medicamento para el tratamiento de enfermedades e infecciones causadas por Acinetobacter baumannii.
PE2018000242A 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii PE20180796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191743 2015-10-27
CN2016100125 2016-09-26

Publications (1)

Publication Number Publication Date
PE20180796A1 true PE20180796A1 (es) 2018-05-09

Family

ID=57200005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000242A PE20180796A1 (es) 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii

Country Status (29)

Country Link
US (3) US10030047B2 (es)
EP (1) EP3368544B1 (es)
JP (2) JP7286317B2 (es)
KR (1) KR20180063138A (es)
CN (1) CN108350028B (es)
AU (1) AU2016347456B2 (es)
CA (1) CA2992926A1 (es)
CL (1) CL2018000978A1 (es)
CO (1) CO2017013708A2 (es)
CR (1) CR20180232A (es)
DK (1) DK3368544T3 (es)
ES (1) ES2811911T3 (es)
HK (1) HK1258443A1 (es)
HR (1) HRP20201273T1 (es)
HU (1) HUE050053T2 (es)
IL (1) IL258060B (es)
MX (2) MX2018005236A (es)
MY (1) MY193014A (es)
NZ (1) NZ738307A (es)
PE (1) PE20180796A1 (es)
PH (1) PH12018500904A1 (es)
PL (1) PL3368544T3 (es)
PT (1) PT3368544T (es)
RS (1) RS60662B1 (es)
RU (1) RU2729609C2 (es)
SI (1) SI3368544T1 (es)
TW (1) TWI720042B (es)
UA (1) UA124303C2 (es)
WO (1) WO2017072062A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192108A (en) * 2014-08-13 2022-07-27 Huawei Tech Co Ltd Fbmc signal transmitting method and receiving method, transmitter and receiver
IL267352B2 (en) 2016-12-21 2023-10-01 Hoffmann La Roche A method for in vitro glycoengineering of antibodies
EP3388444A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) * 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) * 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
JP2022513851A (ja) * 2018-12-17 2022-02-09 エフ．ホフマン－ラ ロシュ アーゲー 抗菌剤としてのイミダゾピラジン誘導体
US11390604B2 (en) 2019-03-08 2022-07-19 Hoffmann-La Roche Inc. Imidazole-pyrazole derivatives
EP4093734A1 (en) 2020-01-22 2022-11-30 F. Hoffmann-La Roche AG Novel heterocyclic compounds
WO2021219578A1 (en) 2020-04-29 2021-11-04 F. Hoffmann-La Roche Ag Antibacterial 8-phenylamino-3-(pyrazol-4-yl)imidazo[1,2-a]pyrazine derivatives
JP2023527479A (ja) 2020-06-01 2023-06-28 エフ． ホフマン－ラ ロシュ アーゲー 新規イミダゾピラジン誘導体
WO2021249893A1 (en) 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Novel imidazo-pyrazine derivatives
CN115916784A (zh) 2020-06-09 2023-04-04 豪夫迈·罗氏有限公司 新型咪唑并吡嗪衍生物
WO2022043486A1 (en) 2020-08-31 2022-03-03 F. Hoffmann-La Roche Ag Imidazole-pyrazole derivatives as antibacterials
WO2022049011A1 (en) 2020-09-01 2022-03-10 F. Hoffmann-La Roche Ag Imidazole-pyrazole derivatives with anti-bacterial properties
CN116096709A (zh) 2020-09-07 2023-05-09 豪夫迈·罗氏有限公司 新型杂环抗生素
CN116829546A (zh) 2021-02-07 2023-09-29 豪夫迈·罗氏有限公司 新型杂芳基取代的咪唑衍生物
WO2023280733A1 (en) 2021-07-06 2023-01-12 F. Hoffmann-La Roche Ag Quaternary ammonium cation substituted compounds for the treatment of bacterial infections
WO2023285497A1 (en) 2021-07-15 2023-01-19 F. Hoffmann-La Roche Ag Imidazole derivatives and their use as antibiotics
WO2023161316A1 (en) 2022-02-25 2023-08-31 F. Hoffmann-La Roche Ag Zwitterionic antibacterial compounds
WO2024033278A1 (en) * 2022-08-09 2024-02-15 F. Hoffmann-La Roche Ag Process for manufacturing an antibiotic macrocyclic peptide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660832B1 (en) * 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
RU2311415C2 (ru) * 2002-08-23 2007-11-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
WO2004111077A1 (en) * 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
EP2316846B1 (en) 2003-07-31 2019-10-02 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
EP1648923B1 (en) 2003-07-31 2008-12-31 Tranzyme Pharma Inc. Spatially-defined macrocycles incorporating peptide bond surrogates
CA2540646A1 (en) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibacterial amide macrocycles
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
DE102004025731A1 (de) * 2004-05-26 2005-12-15 Bayer Healthcare Ag Antibakterielle Amid-Makrozyklen III
US20080161232A1 (en) 2005-01-17 2008-07-03 Jerini Ag C5a Receptor Antagonist
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US8937080B2 (en) 2007-02-08 2015-01-20 Medivir Ab Pyrimidine substituted macrocyclic HCV inhibitors
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
JP2013508410A (ja) * 2009-10-23 2013-03-07 トランザイム・ファーマ，インコーポレイテッド セリンプロテアーゼ酵素の大環状阻害剤を使用する方法
JP2013509434A (ja) 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20130123196A1 (en) 2011-08-31 2013-05-16 New York University Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN103387601B (zh) 2012-05-11 2017-01-11 南开大学 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
MX2015006340A (es) 2012-11-21 2015-09-07 Rqx Pharmaceuticals Inc Antibioticos macrociclicos de amplio espectro.
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Also Published As

Publication number Publication date
HK1258443A1 (zh) 2019-11-15
CL2018000978A1 (es) 2018-08-24
MX2022010520A (es) 2022-09-19
MX2018005236A (es) 2018-08-15
US10030047B2 (en) 2018-07-24
US20180362578A1 (en) 2018-12-20
RU2018113426A3 (es) 2020-01-31
US11098080B2 (en) 2021-08-24
TW201718565A (zh) 2017-06-01
ES2811911T3 (es) 2021-03-15
TWI720042B (zh) 2021-03-01
PH12018500904A1 (en) 2018-11-05
KR20180063138A (ko) 2018-06-11
RS60662B1 (sr) 2020-09-30
PT3368544T (pt) 2020-08-20
CN108350028A (zh) 2018-07-31
RU2018113426A (ru) 2019-11-28
CA2992926A1 (en) 2017-05-04
AU2016347456A1 (en) 2018-01-18
RU2729609C2 (ru) 2020-08-11
EP3368544B1 (en) 2020-06-17
EP3368544A1 (en) 2018-09-05
AU2016347456B2 (en) 2018-12-13
JP2022024009A (ja) 2022-02-08
IL258060A (en) 2018-05-31
WO2017072062A1 (en) 2017-05-04
HRP20201273T1 (hr) 2020-11-13
US20220411468A1 (en) 2022-12-29
SI3368544T1 (sl) 2020-10-30
JP7286317B2 (ja) 2023-06-05
CR20180232A (es) 2018-05-31
HUE050053T2 (hu) 2020-11-30
NZ738307A (en) 2024-02-23
MY193014A (en) 2022-09-22
CO2017013708A2 (es) 2018-03-20
IL258060B (en) 2021-05-31
UA124303C2 (uk) 2021-08-25
CN108350028B (zh) 2021-12-07
US20170233437A1 (en) 2017-08-17
JP2018535960A (ja) 2018-12-06
PL3368544T3 (pl) 2020-11-16
DK3368544T3 (da) 2020-08-24

Similar Documents

Publication Publication Date Title
PE20180796A1 (es) Macrociclos peptidicos contra acinetobacter baumannii
CO2018002060A2 (es) Compuestos farmacéuticos
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CO6771446A2 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CR20180286A (es) Dinucleotidos de purina cíclicos como moduladores de sting
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1